# Sigyn Therapeutics, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Sigyn Therapeutics, Inc.).

## Overview

Sigyn Therapeutics, Inc. is a U.S.-based development-stage medical device company focused on extracorporeal blood purification technologies. Its pipeline includes Sigyn Therapy for infectious disease disorders, along with ChemoPrep and ChemoPure for oncology applications, all designed to operate through hospital dialysis and CRRT infrastructure.

## Products & services

• Sigyn Therapy blood purification device
• ChemoPrep chemotherapy optimization system
• ChemoPure chemotherapy toxicity reduction system
• Pre-clinical and clinical development of extracorporeal therapies

- **Sigyn Therapy** (0%) — Single-use extracorporeal blood purification device designed to remove pathogens, toxins, and cytokines.
- **ChemoPrep** (0%) — Cancer-treatment adjunct intended to reduce circulating exosomes before chemotherapy administration.
- **ChemoPure** (0%) — Post-chemotherapy blood purification concept designed to remove off-target chemotherapy from blood.
- **Research and development** (100%) — Pre-clinical studies, device design, and regulatory advancement for future commercialization.

- Sigyn Therapy blood purification device
- ChemoPrep chemotherapy optimization system
- ChemoPure chemotherapy toxicity reduction system
- Pre-clinical and clinical development of extracorporeal therapies

## Customers

The company is developing products for hospitals, dialysis providers, and clinical centers that treat severe infectious disease, sepsis, endotoxemia, and dialysis-related inflammation. Its oncology concepts are aimed at cancer treatment settings where chemotherapy delivery and toxicity management are important. At this stage, the direct customer base is not commercial buyers but rather clinical investigators, potential hospital users, and future distribution partners.

- **Hospitals and acute care centers** (primary) — Would use Sigyn Therapy for severe infectious disease and inflammatory conditions if cleared.
- **Dialysis and CRRT providers** (primary) — Would deploy the device on existing renal replacement machines for blood purification use cases.
- **Oncology treatment centers** (secondary) — Potential users of ChemoPrep and ChemoPure to improve chemotherapy delivery and reduce toxicity.
- **Clinical research institutions** (secondary) — Support pre-clinical validation and first-in-human studies for the company’s device pipeline.
- **Strategic distribution partners** (emerging) — Would help commercialize cleared products through established healthcare channels.

- Hospitals treating sepsis, endotoxemia, and severe infections
- Dialysis and CRRT providers using existing extracorporeal platforms
- Oncology centers seeking better chemotherapy delivery and tolerability
- Clinical investigators supporting first-in-human and pre-clinical studies
- Future distributors and strategic partners for regulatory commercialization

## Geography

Sigyn Therapeutics is headquartered in San Diego, California and is organized as a Delaware corporation. Its development and future commercialization plans are centered on the United States, while the company describes potential use of its therapies on global dialysis and hospital infrastructure if regulatory clearance is obtained.

- Headquartered in San Diego, California
- Incorporated as a Delaware corporation
- Primary development activity is U.S.-based
- Future use cases are framed for global hospital and dialysis infrastructure

## Strategy

The company’s strategy is to advance Sigyn Therapy through pre-clinical and clinical development toward FDA clearance, while continuing to build its oncology adjunct platform. It also plans to rely on contract manufacturers and component suppliers, and may pursue distribution relationships with healthcare organizations that already serve dialysis, hospital, and oncology markets.

- **Regulatory advancement of Sigyn Therapy** (short-term) — FDA clearance is required before commercialization of the lead device.
- **Clinical validation of oncology platforms** (medium-term) — ChemoPrep and ChemoPure need evidence to support future adoption in cancer care.
- **Manufacturing readiness** (short-term) — Commercialization depends on cGMP-compliant production and reliable suppliers.
- **Strategic channel partnerships** (medium-term) — Established distribution channels could accelerate market access after clearance.

- Advance Sigyn Therapy through pre-clinical and human studies
- Pursue FDA PMA pathway for the Class III device
- Develop ChemoPrep and ChemoPure for oncology applications
- Use contract manufacturers to support cGMP production
- Build partnerships with established healthcare distributors

## Risks

Sigyn is exposed to the risks typical of early-stage medical device developers: regulatory uncertainty, clinical trial failure, and the need for substantial capital before any product revenue. Its business also depends on third-party manufacturers and suppliers, and any interruption in those relationships could delay development or commercialization.

- **FDA regulatory failure or delay** [critical] — Sigyn Therapy is a Class III device requiring PMA approval before market clearance.
- **Clinical development failure** [high] — Pre-clinical and first-in-human results may not support efficacy or safety claims.
- **Financing risk** [critical] — The company states it needs additional capital and has no assurance financing will be available.
- **Supplier and CMO dependency** [high] — Manufacturing relies on third-party vendors and contract manufacturers for components and cGMP output.
- **Market adoption risk** [medium] — Even if cleared, hospitals and dialysis providers must adopt a new extracorporeal therapy.

- No product sales yet; commercialization depends on regulatory success
- Class III device pathway requires extensive pre-clinical and clinical work
- Additional financing is needed to continue operations
- Contract manufacturing and component supply interruptions could delay progress
- Clinical outcomes may not validate the platform across target indications

## Accounting

The company’s financial reporting is dominated by estimates rather than operating revenue, including payroll allocation to research and development and the fair value of warrants. Because it is development-stage, stock-based and derivative-style valuations can materially affect reported results, while any future commercialization would introduce revenue recognition and inventory/manufacturing accounting complexity.

- **Warrant fair value measurement** — Affects reported non-cash expense and balance sheet valuation
- **Use of estimates** — Can materially affect operating expenses and reported losses
- **Research and development cost allocation** — Changes the presentation of R&D versus G&A
- **Future device commercialization accounting** — Could materially change reported revenue timing and margins

- Warrant valuation uses Black-Scholes assumptions and judgment
- Payroll expense allocation affects reported R&D and G&A costs
- Development-stage reporting means limited revenue recognition activity
- Future cGMP manufacturing could add inventory and cost accounting complexity
- Potential future commercialization would require contract and device revenue judgments

---

*Last updated: 2026-04-29T04:58:32.754402+00:00*